Adenosine uptake inhibitors

European Journal of Pharmacology

Volumn 495, Issue 1, 2004, Pages 1-16

  Noji, Tohru ^a   Karasawa, Akira ^a   Kusaka, Hideaki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Adenosine; Adenosine uptake inhibitor (nucleoside transport inhibitor); Protective effect; Therapeutic application

Indexed keywords

5 IODOTUBERCIDIN; ADENOSINE; ADENOSINE KINASE INHIBITOR; ADENOSINE RECEPTOR; BENZODIAZEPINE; CILOSTAZOL; DIHYDROPYRIDINE; DILAZEP; DIPYRIDAMOLE; KF 24345; LIDOFLAZINE; NITROBENZYLTHIOINOSINE; NUCLEOSIDE TRANSPORTER; PROPENTOFYLLINE; QUINAZOLINE DERIVATIVE;

ACUTE PANCREATITIS; BRAIN INJURY; BRAIN ISCHEMIA; CELL DAMAGE; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; GLOMERULONEPHRITIS; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; INSOMNIA; NUCLEOSIDE TRANSPORT; ORGAN TRANSPLANTATION; PAIN; PRIORITY JOURNAL; PROTECTION; PROTEIN INTERACTION; REVIEW; SEIZURE; THROMBOSIS;

ADENOSINE; ANIMALS; BRAIN ISCHEMIA; FORECASTING; HUMANS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MYOCARDIAL REPERFUSION INJURY; NUCLEOSIDE TRANSPORT PROTEINS;

EID: 3042575119     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.05.003     Document Type: Review

References (230)

1. 2-receptor agonists on intrarenal blood flow. Am. J. Physiol. 265:1993;F802-F806
2. Alam M.N., Szymusiak R., Gong H., King J., McGinty D. Adenosinergic modulation of rat basal forebrain neurons during sleep and waking: neuronal recording with microdialysis. J. Physiol. 521:1999;679-690
3. Andine P., Rudolphi K.A., Fredholm B.B., Hagberg H. Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia. Br. J. Pharmacol. 100:1990;814-818
4. Anfossi G., Massucco P., Piretto V., Mularoni E., Cavalot F., Mattiello L., Trovati M. Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates. Clin. Exp. Pharmacol. Physiol. 22:1995;803-811
5. Ashton D., Willems R., De Prins E., Van Belle H., Wauquier A. The nucleoside-transport inhibitor soluflazine (R 64 719) increases the effects of adenosine in the guinea-pig hippocampal slice and is antagonized by adenosine deaminase. Eur. J. Pharmacol. 142:1987;403-408
6. Ashton D., De Prins E., Willems R., Van Belle H., Wauquier A. Anticonvulsant action of the nucleoside transport inhibitor, soluflazine, on synaptic and non-synaptic epileptogenesis in the guinea-pig hippocampus. Epilepsy Res. 2:1988;65-71
7. Baer H.P., Haq A., El-Soofi A., Serignese V., Paterson A.R. Potencies of mioflazine and its derivatives as inhibitors of adenosine transport in isolated erythrocytes from different species. J. Pharm. Pharmacol. 42:1990;367-369
8. Baer H.P., Serignese V., Moorji A., Van Belle H. In vivo effectiveness of several nucleoside transport inhibitors in mice and hamsters. Naunyn-Schmiedeberg's Arch. Pharmacol. 343:1991;365-369
9. Baldwin S.A., Mackey J.R., Cass C.E., Young J.D. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol. Med. Today. 5:1999;216-224
10. Banks P.A. Medical management of acute pancreatitis and complications. Go V.L., DiMagno E.P., Gardner J.D., Lebenthal E., Reber H.A., Scheele G.A. The Pancreas: Biology, Pathobiology, and Disease. 1993;593-611 Raven Press, New York, NY
11. Basheer R., Porkka-Heiskanen T., Strecker R.E., Thakkar M.M., McCarley R.W. Adenosine as a biological signal mediating sleepiness following prolonged wakefulness. Biol. Signals Recept. 9:2000;319-327
12. Baxter G.F. Role of adenosine in delayed preconditioning of myocardium. Cardiovasc. Res. 55:2002;483-494
13. Belardinelli L., Curtis A.B., Bertolet B. Cardiac electrophysiology of adenosine: antiarrhythmic and proarrhythmic actions. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;185-202 Wiley-Liss, New York, NY
14. Booster M.H., Yin M., Maessen J.G., Stubenitsky B.M., Wijnen R.M., Kootstra G. Protection of canine renal grafts by renin-angiotensin inhibition through nucleoside transport blockade. Transpl. Int. 8:1995;207-213
15. Bouma M.G., Stad R.K., van den Wildenberg F.A., Buurman W.A. Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J. Immunol. 153:1994;4159-4168
16. Bouma M.G., van den Wildenberg F.A., Buurman W.A. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. Am. J. Physiol. 270:1996;C522-C529
17. Bruijn J.A., Hogendoorn P.C., Hoedemaeker P.J., Fleuren G.J. The extracellular matrix in pathology. J. Lab. Clin. Med. 111:1988;140-149
18. Bullough D.A., Magill M.J., Firestein G.S., Mullane K.M. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. J. Immunol. 155:1995;2579-2586
19. Buolamwini J.K. Nucleoside transport inhibitors: structure-activity relationships and potential therapeutic applications. Curr. Med. Chem. 4:1997;35-66
20. Burnstock G., Wood J.N. Purinergic receptors: their role in nociception and primary afferent neurotransmission. Curr. Opin. Neurobiol. 6:1996;526-532
21. Burnstock G., Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. J. Pharmacol. Exp. Ther. 295:2000;862-869
22. Cabrita M.A., Baldwin S.A., Young J.D., Cass C.E. Molecular biology and regulation of nucleoside and nucleobase transporter proteins in eukaryotes and prokaryotes. Biochem. Cell. Biol. 80:2002;623-638
23. Camussi G. Interactive effects of tumor necrosis factor and platelet-activating factor in the pathogenesis of glomerular injury. Lab. Invest. 70:1994;435-436
24. Casado F.J., Lostao M.P., Aymerich I., Larrayoz I.M., Duflot S., Rodriguez-Mulero S., Pastor-Anglada M. Nucleoside transporters in absorptive epithelia. J. Physiol. Biochem. 58:2002;207-216
25. Cass C.E., Young J.D., Baldwin S.A. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem. Cell. Biol. 76:1998;761-770
26. Cass C.E., Young J.D., Baldwin S.A., Cabrita M.A., Graham K.A., Griffiths M., Jennings L.L., Mackey J.R., Ng A.M., Ritzel M.W., Vickers M.F., Yao S.Y. Nucleoside transporters of mammalian cells. Pharm. Biotechnol. 12:1999;313-352
27. Castillo-Melendez M., Jarrott B., Lawrence A.J. Radioligand binding and autoradiographic visualization of adenosine transport sites in human inferior vagal ganglia and their axonal transport along rat vagal afferent neurons. J. Auton. Nerv. Syst. 57:1996;36-42
28. Chan T.C., Howell S.B. Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity. Eur. J. Cancer. 26:1990;907-911
29. Chang-Chun C., Masuda M., Szabo Z., Szerafin T., Szecsi J., Van Belle H., Flameng W. Nucleoside transport inhibition mediates lidoflazine-induced cardioprotection during intermittent aortic crossclamping. J. Thorac. Cardiovasc. Surg. 104:1992;1602-1609
30. Churchill P.C., Bidani A. Renal effects of selective adenosine receptor agonists in anesthetized rats. Am. J. Physiol. 252:1987;F299-F303
31. Collis M.G., Hourani S.M. Adenosine receptor subtypes. Trends Pharmacol. Sci. 14:1993;360-366
32. Conant A.R., Jarvis S.M. Nucleoside influx and efflux in guinea-pig ventricular myocytes. Inhibition by analogues of lidoflazine. Biochem. Pharmacol. 48:1994;873-880
33. 2A receptor agonists. Curr. Topics Med. Chem. 3:2003;387-401
34. Cronstein B.N. Adenosine, an endogenous anti-inflammatory agent. J. Appl. Physiol. 76:1994;5-13
35. Cronstein B.N. A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. J. Investig. Med. 43:1995;50-57
36. Cronstein B.N. Adenosine regulation of neutrophil function and inhibition of inflammation via adenosine receptors. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;285-299 Wiley-Liss, New York, NY
37. Cronstein B.N., Levin R.I., Belanoff J., Weissmann G., Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J. Clin. Invest. 78:1986;760-770
38. Cronstein B.N., Naime D., Ostad E. The antiinflammatory mechanism of methotrexate. J. Clin. Invest. 92:1993;2675-2682
39. 1-acid glycoprotein binding. Br. J. Cancer. 80:1999;1738-1746
40. 1 receptor: analysis of the potential therapeutic effects obtained by its activation in the central nervous system. Curr. Med. Chem. 9:2002;1923-1937
41. Dar M.S. Central nervous system effects and behavioral interactions with ethanol of centrally administered dilazep and its metabolites in mice. Eur. J. Pharmacol. 164:1989;303-313
42. Dawicki D.D., Agarwal K.C., Parks R.E. Jr. Potentiation of the antiplatelet action of adenosine in whole blood by dipyridamole or dilazep and the cAMP phosphodiesterase inhibitor, RA 233. Thromb. Res. 43:1986;161-175
43. Deckert J., Gleiter C.H. Adenosine - an endogenous neuroprotective metabolite and neuromodulator. J. Neural Transm., Suppl. 43:1994;23-31
44. 3H]nitrobenzylthioinosine binding to the adenosine transporter in human brain. Eur. J. Pharmacol. 238:1993;131-133
45. Deguchi H., Takeya H., Wada H., Gabazza E.C., Hayashi N., Urano H., Suzuki K. Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes. Blood. 90:1997;2345-2356
46. Deguchi H., Takeya H., Urano H., Gabazza E.C., Zhou H., Suzuki K. Adenosine regulates tissue factor expression on endothelial cells. Thromb. Res. 91:1998;57-64
47. De Hert S.G., Rodrigus I.E., Haenen L.R., Broecke P.W., Boeckxstaens C.J., Gillebert T.C. Effects of lidoflazine on left ventricular function in patients. J. Cardiothorac. Vasc. Anesth. 1:1997;42-48
48. de Jong J.W., van der Meer P., van Loon H., Owen P., Opie L.H. Adenosine as adjunct to potassium cardioplegia: effect on function, energy metabolism, and electrophysiology. J. Thorac. Cardiovasc. Surg. 100:1990;445-454
49. de Jong J.W., de Jonge R., Keijzer E., Bradamante S. The role of adenosine in preconditioning. Pharmacol. Ther. 87:2000;141-149
50. 1 receptors: partial and inverse agonism. Curr. Pharm. Des. 8:2002;2333-2344
51. Denham W., Yang J., Fink G., Denham D., Carter G., Ward K., Norman J. Gene targeting demonstrates additive detrimental effects of interleukin 1 and tumor necrosis factor during pancreatitis. Gastroenterology. 113:1997;1741-1746
52. Dennis D.M., Raatikainen M.J., Martens J.R., Belardinelli L. Modulation of atrioventricular nodal function by metabolic and allosteric regulators of endogenous adenosine in guinea pig heart. Circulation. 94:1996;2551-2559
53. De Schryver E.L., Algra A., van Gijn J. Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke. 34:2003;2072-2080
54. Dickenson A.H., Suzuki R., Reeve A.J. Adenosine as a potential analgesic target in inflammatory and neuropathic pains. CNS Drugs. 13:2000;77-85
55. Dogne J., de Leval X., Benoit P., Delarge J., Masereel B., David J. Recent advances in antiplatelet agents. Curr. Med. Chem. 9:2002;577-589
56. Dunwiddie T.V. Adenosine and suppression of seizures. Adv. Neurol. 79:1999;1001-1010
57. Dunwiddie T.V., Diao L. Regulation of extracellular adenosine in rat hippocampal slices is temperature dependent: role of adenosine transporters. Neuroscience. 95:2000;81-88
58. Dunwiddie T.V., Masino S.A. The role and regulation of adenosine in the central nervous system. Annu. Rev. Neurosci. 24:2001;31-55
59. Dux E., Fastbom J., Ungerstedt U., Rudolphi K., Fredholm B.B. Protective effect of adenosine and a novel xanthine derivative propentofylline on the cell damage after bilateral carotid occlusion in the gerbil hippocampus. Brain Res. 516:1990;248-256
60. Elam M.B., Heckman J., Crouse J.R., Hunninghake D.B., Herd J.A., Davidson M., Gordon I.L., Bortey E.B., Forbes W.P. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler. Thromb. Vasc. Biol. 18:1998;1942-1947
61. Ely S.W., Berne R.M. Protective effects of adenosine in myocardial ischemia. Circulation. 85:1992;893-904
62. Figueredo V.M., Diamond I., Zhou H., Camacho S.A. Chronic dipyridamole therapy produces sustained protection against cardiac ischemia-reperfusion injury. Am. J. Physiol. 77:1999;H2091-H2097
63. Filtz T.M., Harden T.K., Nicholas R.A. Structure, pharmacological selectivity, and second messenger signaling properties of G protein-coupled P2-purinergic receptors. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;39-53 Wiley-Liss, New York, NY
64. Flameng W., Sukehiro S., Mollhoff T., Van Belle H., Janssen P. A new concept of long-term donor heart preservation: nucleoside transport inhibition. J. Heart Lung Transplant. 10:1991;990-998
65. Foster A.C., Miller L.P., Wiesner J.B. Regulation of endogenous adenosine levels in the CNS: potential for therapy in stroke, epilepsy and pain. Adv. Exp. Med. Biol. 370:1994;427-430
66. Fredholm B.B. Adenosine and neuroprotection. Int. Rev. Neurobiol. 40:1997;259-280
67. Fredholm B.B., Fastbom J., Kvanta A., Gerwins P., Parkinson F. Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport. Fundam. Clin. Pharmacol. 6:1992;99-111
68. Fredholm B.B., Arslan G., Halldner L., Kull B., Schulte G., Wasserman W. Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Arch. Pharmacol. 362:2000;364-374
69. Fredholm B.B., IJzerman A.P., Jacobson K.A., Klotz K., Linden J. International union of pharmacology: XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53:2001;527-552
70. Fremes S.E., Furukawa R.D., Zhang J., Li R., Tumiati L.C., Weisel R.D., Mickle D.A. Cardiac storage with University of Wisconsin solution and a nucleoside-transport blocker. Ann. Thorac. Surg. 59:1995;1127-1133
71. Gadangi P., Longaker M., Naime D., Levin R.I., Recht P.A., Montesinos M.C., Buckley M.T., Carlin G., Cronstein B.N. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J. Immunol. 156:1996;1937-1941
72. Galinanes M., Hearse D.J. Exogenous adenosine accelerates recovery of cardiac function and improves coronary flow after long-term hypothermic storage and transplantation. J. Thorac. Cardiovasc. Surg. 104:1992;151-158
73. Galinanes M., Qiu Y., Van Belle H., Hearse D.J. Metabolic and functional effects of the nucleoside transport inhibitor R75231 in the ischaemic and blood reperfused rabbit heart. Cardiovasc. Res. 27:1993;90-95
74. Geiger J.D., Parkinson F.E., Kowaluk E.A. Regulators of endogenous adenosine levels as therapeutic agents. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;55-84 Wiley-Liss, New York, NY
75. Gidday J.M., Fitzgibbons J.C., Shah A.R., Kraujalis M.J., Park T.S. Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. Pediatr. Res. 38:1995;306-311
76. Gidday J.M., Kim Y., Shah A.R., Gonzales E.R., Park T.S. Adenosine transport inhibition ameliorates postischemic hypoperfusion in pigs. Brain Res. 734:1996;261-268
77. Grady T., Liang P., Ernst S.A., Logsdon C.D. Chemokine gene expression in rat pancreatic acinar cells is an early event associated with acute pancreatitis. Gastroenterology. 113:1997;1966-1975
78. Gresele P., Arnout J., Deckmyn H., Vermylen J. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb. Haemost. 55:1986;12-18
79. Griffith D.A., Jarvis S.M. Nucleoside and nucleobase transport systems of mammalian cells. Biochim. Biophys. Acta. 1286:1996;153-181
80. Griffiths M., Beaumont N., Yao S.Y., Sundaram M., Boumah C.E., Davies A., Kwong F.Y., Coe I., Cass C.E., Young J.D., Baldwin S.A. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat. Med. 3:1997;89-93
81. 1 receptor activation. J. Pharmacol. Exp. Ther. 268:1994;90-96
82. Hammond J.R., Archer R.G. Interaction of the novel adenosine uptake inhibitor 3-[1-(6, 7-diethoxy-2-morpholinoquinazolin-4-yl)piperidin-4-yl]-1, 6-dimethyl-2, 4(1H, 3H)-quinazolinedione hydrochloride (KF24345) with the es and ei subtypes of equilibrative nucleoside transporters. J. Pharmacol. Exp. Ther. 308:2004;1083-1093
83. Harker L.A., Kadatz R.A. Mechanism of action of dipyridamole. Thromb. Res. 4:1983;39-46
84. Hasko G., Deitch E.A., Szabo C., Nemeth Z.H., Vizi E.S. Adenosine: a potential mediator of immunosuppression in multiple organ failure. Curr. Opin. Pharmacol. 2:2002;440-444
85. Headrick J.P., Matherne G.P., Berne R.M. Myocardial adenosine formation during hypoxia: effects of ecto-5′-nucleotidase inhibition. J. Mol. Cell. Cardiol. 24:1992;295-303
86. Heaton T.P., Clanachan A.S. Nucleoside transport in guinea pig myocytes. Comparison of the affinities and transport velocities for adenosine and 2-chloroadenosine. Biochem. Pharmacol. 36:1987;1275-1280
87. Hyde R.J., Cass C.E., Young J.D., Baldwin S.A. The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol. Membr. Biol. 18:2001;53-63
88. IJzerman A.P., van der Wenden N.M. Modulators of adenosine uptake, release, and inactivation. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;129-148 Wiley-Liss, New York, NY
89. 3H]nitrobenzylthioinosine binding. Naunyn-Schmiedeberg's Arch. Pharmacol. 345:1992;558-563
90. Itoya M., Miura T., Sakamoto J., Urabe K., Iimura O. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J. Cardiovasc. Pharmacol. 24:1994;846-852
91. Izumino K., Iida H., Asaka M., Mizumura Y., Sasayama S. Effect of the antiplatelet agents ticlopidine and dipyridamole on experimental immune complex glomerulonephritis in rats. Nephron. 43:1986;56-61
92. Jackson E.K. Renal actions of purines. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;217-250 Wiley-Liss, New York, NY
93. Jacobson K.A., van Rhee A.M. Development of selective purinoceptor agonists and antagonists. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;101-128 Wiley-Liss, New York, NY
94. Jacobson K.A., van Galen P.J., Williams M. Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. J. Med. Chem. 35:1992;407-422
95. Johnson S.M., Patel S., Bruckner F.E., Collins D.A. 5′-Nucleotidase as a marker of both general and local inflammation in rheumatoid arthritis patients. Rheumatology (Oxf.). 38:1999;391-396
96. Kano T., Katayama Y., Kawamata T., Hirota H., Tsubokawa T. Propentofylline administered by microdialysis attenuates ischemia-induced hippocampal damage but not excitatory amino acid release in gerbils. Brain Res. 641:1994;149-154
97. Kawahara N., Ide T., Saito N., Kawai K., Kirino T. Propentofylline potentiates induced ischemic tolerance in gerbil hippocampal neurons via adenosine receptor. J. Cereb. Blood Flow Metab. 18:1998;472-475
98. Keil G.J. II, Delander G.E. Time-dependent antinociceptive interactions between opioids and nucleoside transport inhibitors. J. Pharmacol. Exp. Ther. 274:1995;1387-1392
99. Khakh B.S., Kennedy C. Adenosine and ATP: progress in their receptors' structures and functions. Trends Pharmacol. Sci. 19:1998;39-41
100. Kirkeboen K.A., Aksnes G., Lande K., Ilebekk A. Role of adenosine for reactive hyperemia in normal and stunned porcine myocardium. Am. J. Physiol. 263:1992;H1119-H1127
101. Kirkeboen K.A., Ilebekk A., Tonnessen T., Leistad E., Naess P.A., Christensen G., Aksnes G. Cardiac contractile function following repetitive brief ischemia: effects of nucleoside transport inhibition. Am. J. Physiol. 267:1994;H57-H65
102. Kitakaze M., Hori M., Kamada T. Role of adenosine and its interaction with (adrenoceptor activity in ischaemic and reperfusion injury of the myocardium. Cardiovasc. Res. 27:1993;18-27
103. Kitakaze M., Hori M., Takashima S., Sato H., Inoue M., Kamada T. Ischemic preconditioning increases adenosine release and 5'-nucleotidase activity during myocardial ischemia and reperfusion in dogs: implications for myocardial salvage. Circulation. 87:1993;208-215
104. Knutsen L.J., Murray T.F. Adenosine and ATP in Epilepsy. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;423-447 Wiley-Liss, New York, NY
105. ++ influx-sensitive ventricular arrhythmias. Jpn. Circ. J. 60:1996;629-640
106. Kohda N., Tani T., Nakayama S., Adachi T., Marukawa K., Ito R., Ishida K., Matsumoto Y., Kimura Y. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb. Res. 96:1999;261-268
107. Kollias-Baker C., Xu J., Pelleg A., Belardinelli L. Novel approach for enhancing atrioventricular nodal conduction delay mediated by endogenous adenosine. Circ. Res. 75:1994;972-980
108. Konturek S.J., Dembinski A., Konturek P.J., Warzecha Z., Jaworek J., Gustaw P., Tomaszewska R., Stachura J. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut. 33:1992;1268-1274
109. Koos W.T., Perneczky A., Auer L.M., Boker D.K., Gaab M., Jaksche H., Kostron H., Meinig G., Muizelaar J.P., van der Werf A.J., Seibert H.K., Ulrich F., Sprung C. Nimodipine treatment of ischemic neurological deficits due to cerebral vasospasm after subarachnoid hemorrhage. Neurochirurgia. 28:1985;114-117
110. Kowaluk E.A., Bhagwat S.S., Jarvis M.F. Adenosine kinase inhibitors. Curr. Pharm. Des. 4:1998;403-416
111. Krump E., Borgeat P. Adenosine. An endogenous inhibitor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Adv. Exp. Med. Biol. 447:1999;107-115
112. Lasley R.D., Mentzer R.M. Jr. The role of adenosine in extended myocardial preservation with the University of Wisconsin solution. J. Thorac. Cardiovasc. Surg. 107:1994;1356-1363
113. Latini S., Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J. Neurochem. 79:2001;463-484
114. Leach S.D., Modlin I.M., Scheele G.A., Gorelick F.S. Intracellular activation of digestive zymogens in rat pancreatic acini. Stimulation by high doses of cholecystokinin. J. Clin. Invest. 87:1991;362-366
115. 2T-receptor antagonists as novel antithrombotic agents. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;203-216 Wiley-Liss, New York, NY
116. Lemasters J.J., Thurman R.G. Reperfusion injury after liver preservation for transplantation. Annu. Rev. Pharmacol. Toxicol. 37:1997;327-338
117. Le Vraux V., Chen Y.L., Masson I., De Sousa M., Giroud J.P., Florentin I., Chauvelot-Moachon L. Inhibition of human monocyte TNF production by adenosine receptor agonists. Life Sci. 52:1993;1917-1924
118. Liang B.T., Jacobson K.A. Adenosine and ischemic preconditioning. Curr. Pharm. Des. 5:1999;1029-1041
119. Linden J. Allosteric enhancement of adenosine receptors. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;85-97 Wiley-Liss, New York, NY
120. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Annu. Rev. Pharmacol. Toxicol. 41:2001;775-787
121. Liu Y., Fong M., Cone J., Wang S., Yoshitake M., Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J. Cardiovasc. Pharmacol. 36:2000;351-360
122. Liu Y., Shakur Y., Yoshitake M., Kambayashi J. Cilostazol (Pletal®): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc. Drug Rev. 19:2001;369-386
123. 3H]Nitrobenzylthioinosine binding as a probe for the study of adenosine uptake sites in brain. J. Neurochem. 39:1982;184-191
124. Martin B.J., Lasley R.D., Mentzer R.M. Jr. Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine. Am. J. Physiol. 272:1997;H1857-H1865
125. Marzilli M., Simonetti I., Levantesi D., Trivella M.G., De Nes M., Perissinotto A., Puntoni R., Buzzigoli G., Boni C., Michelassi C., L'Abbate A. Effects of dilazep on coronary and systemic hemodynamics in humans. Am. Heart J. 108:1984;276-285
126. Masuda M., Chang-Chun C., Mollhoff T., Van Belle H., Flameng W. Effects of nucleoside transport inhibition on long-term ex vivo preservation of canine hearts. J. Thorac. Cardiovasc. Surg. 104:1992;1610-1617
127. Minami N., Suzuki Y., Yamamoto M., Kihira H., Imai E., Wada H., Kimura Y., Ikeda Y., Shiku H., Nishikawa M. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 61:1997;PL 383-PL 389
128. Minamino T., Kitakaze M., Komamura K., Node K., Takeda H., Inoue M., Hori M., Kamada T. Activation of protein kinase C increases adenosine production in the hypoxic canine coronary artery through the extracellular pathway. Arterioscler. Thromb. Vasc. Biol. 15:1995;2298-2304
129. Mitchell J.B., Lupica C.R., Dunwiddie T.V. Activity-dependent release of endogenous adenosine modulates synaptic responses in the rat hippocampus. J. Neurosci. 13:1993;3439-3447
130. Miyashita K., Nakajima T., Ishikawa A., Miyatake T. An adenosine uptake blocker, propentofylline, reduces glutamate release in gerbil hippocampus following transient forebrain ischemia. Neurochem. Res. 17:1992;147-150
131. Mollhoff T., Sukehiro S., Van Belle H., Van Aken H., Flameng W. Successful transplantation after long-term preservation of dog hearts. Anesthesiology. 77:1992;291-300
132. Moser G.H., Schrader J., Deussen A. Turnover of adenosine in plasma of human and dog blood. Am. J. Physiol. 256:1989;C799-C806
133. Mubagwa K., Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc. Res. 52:2001;25-39
134. Mullane K., Bullough D. Harnessing an endogenous cardioprotective mechanism: cellular sources and sites of action of adenosine. J. Mol. Cell. Cardiol. 27:1995;1041-1054
135. Murray R.D., Churchill P.C. Concentration dependency of the renal vascular and renin secretory responses to adenosine receptor agonists. J. Pharmacol. Exp. Ther. 232:1985;189-193
136. Murray T.F., Sylvester D., Schultz C.S., Szot P. Purinergic modulation of the seizure threshold for pentylenetetrazol in the rat. Neuropharmacology. 24:1985;761-766
137. Nakamura T., Ushiyama C., Shimada N., Sekizuka K., Ebihara I., Hara M., Koide H. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care. 23:2000;1168-1171
138. Narimatsu E., Aoki M. Involvement of the adenosine neuromodulatory system in the benzodiazepine-induced depression of excitatory synaptic transmissions in rat hippocampal neurons in vitro. Neurosci. Res. 33:1999;57-64
139. Narimatsu E., Aoki M. Transient depression of excitatory synaptic transmission induced by adenosine uptake inhibition in rat hippocampal slices. Brain Res. 862:2000;284-287
140. Niederau C., Ude K., Niederau M., Luthen R., Strohmeyer G., Ferrell L.D., Grendell J.H. Effects of the seleno-organic substance Ebselen in two different models of acute pancreatitis. Pancreas. 6:1991;282-290
141. Niederau C., Niederau M., Borchard F., Ude K., Luthen R., Strohmeyer G., Ferrell L.D., Grendell J.H. Effects of antioxidants and free radical scavengers in three different models of acute pancreatitis. Pancreas. 7:1992;486-496
142. Noji T., Sato H., Sano J., Nishikawa S., Kusaka H., Karasawa A. Treatment with an adenosine uptake inhibitor attenuates glomerulonephritis in mice. Eur. J. Pharmacol. 449:2002;293-300
143. Noji T., Takayama M., Mizutani M., Okamura Y., Takai H., Karasawa A., Kusaka H. KF24345, an adenosine uptake inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor-α production and leukopenia via endogenous adenosine in mice. J. Pharmacol. Exp. Ther. 300:2002;200-205
144. Noji T., Nan-ya K., Katagiri C., Mizutani M., Sano J., Nishikawa S., Karasawa A., Kusaka H. Adenosine uptake inhibition ameliorates cerulein-induced acute pancreatitis in mice. Pancreas. 25:2002;387-392
145. Noji T., Nan-ya K., Mizutani M., Katagiri C., Sano J., Ttakada C., Nishikawa S., Karasawa A., Kusaka H. KF24345, an adenosine uptake inhibitor, ameliorates the severity and mortality of lethal acute pancreatitis via endogenous adenosine in mice. Eur. J. Pharmacol. 454:2002;85-93
146. O'Connor S.D., Stojanovic M., Radulovacki M. The effect of soluflazine on sleep in rats. Neuropharmacology. 30:1991;671-674
147. Ogawa M. Acute pancreatitis and cytokines: "second attack" by septic complication leads to organ failure. Pancreas. 16:1998;312-315
148. Ohta A., Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature. 414:2001;916-920
149. Olah M.E., Stiles G.L. The role of receptor structure in determining adenosine receptor activity. Pharmacol. Ther. 85:2000;55-75
150. O'Meara Y.M., Brady H.R. Lipoxins, leukocyte recruitment and the resolution phase of acute glomerulonephritis. Kidney Inter., Suppl. 58:1997;S56-S61
151. Osswald H., Nabakowski G., Hermes H. Adenosine as a possible mediator of metabolic control of glomerular filtration rate. Int. J. Biochem. 12:1980;263-267
152. Park T.S., Gidday J.M. Effect of dipyridamole on cerebral extracellular adenosine level in vivo. J. Cereb. Blood Flow Metab. 10:1990;424-427
153. 2 receptors and nitrobenzylthioinosine-sensitive nucleoside transporters: quantitative autoradiographic analysis. Eur. J. Pharmacol. 202:1991;361-366
154. 1 MF-2 smooth muscle cells. J. Pharmacol. Exp. Ther. 277:1996;1397-1401
155. 3H]adenosine influx. A study of three nucleoside transport systems. Biochem. Pharmacol. 46:1993;891-896
156. Parkinson F.E., Rudolphi K.A., Fredholm B.B. Propentofylline: a nucleoside transport inhibitor with neuroprotective effects in cerebral ischemia. Gen. Pharmacol. 25:1994;1053-1058
157. Parmely M.J., Zhou W., Edwards C.K. III, Borcherding D.R., Silverstein R., Morrison D.C. Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-α production and protect mice against endotoxin challenge. J. Immunol. 151:1993;389-396
158. Pasini F.L., Capecchi P.L., Perri T.D. Adenosine and chronic ischemia of the lower limbs. Vasc. Med. 5:2000;243-250
159. 3H]nitrobenzylthioinosine binding to adenosine uptake sites in brain. Neurosci. Lett. 29:1982;79-82
160. 2A receptors in ischemia. Ann. N.Y. Acad. Sci. 939:2001;74-84
161. Pelleg A. Mechanisms of action and therapeutic potential of adenosine and its analogues in the treatment of cardiac arrhythmias. Coron. Artery Dis. 4:1993;109-115
162. Pelleg A., Pennock R.S., Kutalek S.P. Proarrhythmic effects of adenosine: one decade of clinical data. Am. J. Ther. 9:2002;141-147
163. Petsikas D., Ricci M.A., Baffour R., de Varennes B., Symes J., Guerraty A. Enhanced 24-hour in vitro heart preservation with adenosine and adenosine monophosphate. J. Heart Transplant. 9:1990;114-118
164. Phillis J.W., Goshgarian H.G. Adenosine and neurotrauma: therapeutic perspectives. Neurol. Res. 23:2001;183-189
165. Picano E., Michelassi C. Chronic oral dipyridamole as a 'novel'
166. Plagemann P.G., Wohlhueter R.M., Kraupp M. Adenosine uptake, transport, and metabolism in human erythrocytes. J. Cell. Physiol. 125:1985;330-336
167. Poelstra K., Brouwer E., Baller J.F., Hardonk M.J., Bakker W.W. Attenuation of anti-Thy1 glomerulonephritis in the rat by anti-inflammatory platelet-inhibiting agents. Am. J. Pathol. 142:1993;441-450
168. Porkka-Heiskanen T. Adenosine in sleep and wakefulness. Ann. Med. 31:1999;125-129
169. Porkka-Heiskanen T., Strecker R.E., Thakkar M., Bjorkum A.A., Greene R.W., McCarley R.W. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science. 276:1997;1265-1268
170. Porkka-Heiskanen T., Alanko L., Kalinchuk A., Stenberg D. Adenosine and sleep. Sleep Med. Rev. 6:2002;321-332
171. Poulsen S.A., Quinn R.J. Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. 6:1998;619-641
172. Qian J.Q., Batink H.D., Timmermans P.B., van Zwieten P.A. Interaction between dilazep and α-adrenoceptors. Pharmacology. 29:1984;198-203
173. Quere I., Hillaire-Buys D., Brunschwig C., Chapal J., Janbon C., Blayac J.P., Petit P., Loubatieres-Mariani M.M. Effects of homocysteine on acetylcholine- and adenosine-induced vasodilatation of pancreatic vascular bed in rats. Br. J. Pharmacol. 122:1997;351-357
174. Ralevic V., Burnstock G. Receptors for purines and pyrimidines. Pharmacol. Rev. 50:1998;413-492
175. 2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase. J. Biol. Chem. 271:1996;17114-17118
176. Ribeiro J.A., Sebastiao A.M., de Mendonca A. Participation of adenosine receptors in neuroprotection. Drug News Perspect. 16:2003;80-86
177. Ritzel M.W., Ng A.M., Yao S.Y., Graham K., Loewen S.K., Smith K.M., Hyde R.J., Karpinski E., Cass C.E., Baldwin S.A., Young J.D. Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). Mol. Membr. Biol. 18:2001;65-72
178. Rosengren S., Firestein G.S. Purinergic modulation of septic shock and systemic inflammation response syndrome. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;301-313 Wiley-Liss, New York, NY
179. Saluja A.K., Steer M.L. Pathophysiology of pancreatitis. Role of cytokines and other mediators of inflammation. Digestion. 60(Suppl. 1):1999;27-33
180. Sawynok J. Purines and nociception. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;495-513 Wiley-Liss, New York, NY
181. Sawynok J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 317:1998;1-11
182. Sawynok J., Liu X.J. Adenosine in the spinal cord and periphery: release and regulation of pain. Prog. Neurobiol. 69:2003;313-340
183. Sawynok J., Sweeney M.I., White T.D. Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br. J. Pharmacol. 88:1986;923-930
184. Schrier D.J., Lesch M.E., Wright C.D., Gilbertsen R.B. The antiinflammatory effects of adenosine receptor agonists on the carrageenan-induced pleural inflammatory response in rats. J. Immunol. 145:1990;1874-1879
185. Schror K. The pharmacology of cilostazol. Diabetes Obes. Metab. 4:2002;S14-S19
186. Scriabine A., Schuurman T., Traber J. Pharmacological basis for the use of nimodipine in central nervous system disorders. FASEB J. 3:1989;1799-1806
187. Seif-El-Nasr M., Khattab M. Influence of inhibition of adenosine uptake on the γ-aminobutyric acid level of the ischemic rat brain. Arzneim.-Forsch./Drug Res. 52:2002;353-357
188. 2A- but not A1-receptor-mediated effects of adenosine. Role of nucleoside transport inhibition and clinical implications. Anesthesiology. 92:2000;567-577
189. Shi M.M., Wu J.R., Lee C., Young J.D. Nucleoside transport. Photoaffinity labelling of high-affinity nitrobenzylthioinosine binding sites in rat and guinea pig lung. Biochem. Biophys. Res. Commun. 118:1984;594-600
190. Sinclair C.J., Krizanac-Bengez L., Stanness K.A., Janigro D., Parkinson F.E. Adenosine permeation of a dynamic in vitro blood-brain barrier inhibited by dipyridamole. Brain Res. 898:2001;122-125
191. 2A adenosine receptor as a physiological immunosuppressor and to engineer inflammation in vivo. Biochem. Pharmacol. 65:2003;493-501
192. Smith P.G., Thomas H.D., Barlow H.C., Griffin R.J., Golding B.T., Calvert A.H., Newell D.R., Curtin N.J. In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity. Clin. Cancer Res. 7:2001;2105-2113
193. Sollevi A. Adenosine for pain control. Acta Anaesthesiol. Scand., Suppl. 110:1997;135-136
194. Sommerschild H.T., Grund F., Offstad J., Jynge P., Ilebekk A., Kirkeboen K.A. Importance of endogenous adenosine during ischemia and reperfusion in neonatal porcine hearts. Circulation. 96:1997;3094-3103
195. Southard J.H., Belzer F.O. Organ preservation. Annu. Rev. Med. 46:1995;235-247
196. Steer M.L. Etiology and pathophysiology of acute pancreatitis. Go V.L., DiMagno E.P., Gardner J.D., Lebenthal E., Reber H.A., Scheele G.A. The Pancreas: Biology, Pathobiology, and Disease. 1993;581-592 Raven Press, New York, NY
197. Steinberg W., Tenner S. Acute pancreatitis. N. Engl. J. Med. 330:1994;1198-1210
198. Steinle A.U., Weidenbach H., Wagner M., Adler G., Schmid R.M. NF-κB/Rel activation in cerulein pancreatitis. Gastroenterology. 116:1999;420-430
199. Stiles G.L. Adenosine receptor subtypes: new insights from cloning and functional studies. Jacobson K.A., Jarvis M.F. Purinergic Approaches in Experimental Therapeutics. 1997;29-37 Wiley-Liss, New York, NY
200. Stratta P., Canavese C., Sandri L., Ciccone G., Santi S., Barolo S., Messuerotti A., Quaglia M., Mazzucco G., Fop F., Segoloni G.P., Piccoli G. The concept of 'glomerulonephritis'. The fascinating history of evolution and emergence of a specialist's nosology focus on Italy and Trino. Am. J. Nephrol. 19:1999;83-91
201. 2+ -antagonist binding sites. Evidence for an unusual receptor coupled to the nucleoside transporter. Eur. J. Biochem. 150:1985;67-77
202. Sun B., Le S.N., Lin S., Fong M., Guertin M., Liu Y., Tandon N.N., Yoshitake M., Kambayashi J. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. J. Cardiovasc. Pharmacol. 40:2002;577-585
203. Sweeney M.I. Neuroprotective effects of adenosine in cerebral ischemia: window of opportunity. Neurosci. Biobehav. Rev. 21:1997;207-217
204. 2 receptor antagonist, vapiprost, and other antiplatelet drugs on arterial thrombosis in rats: possible role of TXA2. Thromb. Haemost. 68:1992;460-463
205. 1 receptor-mediated mechanisms in the juvenile rat hippocampus. J. Pharmacol. Exp. Ther. 286:1998;1412-1419
206. Thorn J.A., Jarvis S.M. Adenosine transporters. Gen. Pharmacol. 27:1996;613-620
207. Todo S., Zhu Y., Zhang S., Jin M.B., Ishizaki N., Tanaka H., Subbotin V., Starzl T.E. Attenuation of ischemic liver injury by augmentation of endogenous adenosine. Transplantation. 63:1997;217-223
208. Toombs C.F., McGee D.S., Johnston W.E., Vinten-Johansen J. Myocardial protective effects of adenosine. Infarct size reduction with pretreatment and continued receptor stimulation during ischemia. Circulation. 86:1992;986-994
209. Van Belle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiovasc. Res. 27:1993;68-76
210. Van Belle H., Janssen P.A. Comparative pharmacology of nucleoside transport inhibitors. Nucleosides Nucleotides. 10:1991;975-982
211. Van Belle H., Wynants J., Xhonneux R., Flameng W. Changes in creatine phosphate, inorganic phosphate, and the purine pattern in dog hearts with time of coronary artery occlusion and effect thereon of mioflazine, a nucleoside transport inhibitor. Cardiovasc. Res. 20:1986;658-664
212. Van Belle H., Goossens F., Wynants J. Biochemical and functional effects of nucleoside transport inhibition in the isolated cat heart. J. Mol. Cell. Cardiol. 21:1989;797-805
213. 3 receptor and its ligands. Prog. Med. Chem. 38:2001;61-113
214. Verma A., Marangos P.J. Nitrobenzylthioinosine binding in brain: an interspecies study. Life Sci. 36:1985;283-290
215. von Lubitz D.K. Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? Eur. J. Pharmacol. 371:1999;85-102
216. von Lubitz D.K. Adenosine in the treatment of stroke: yes, maybe, or absolutely not? Expert Opin. Investig. Drugs. 10:2001;619-632
217. von Lubitz D.K., Dambrosia J.M., Kempski O., Redmond D.J. Cyclohexyl adenosine protects against neuronal death following ischemia in the CA1 region of gerbil hippocampus. Stroke. 19:1988;1133-1139
218. Wainwright C.L., Parratt J.R., Van Belle H. The antiarrhythmic effects of the nucleoside transporter inhibitor. R75231, in anaesthetized pigs. Br. J. Pharmacol. 109:1993;592-599
219. Wang J., Schaner M.E., Thomassen S., Su S.F., Piquette-Miller M., Giacomini K.M. Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. Pharm. Res. 14:1997;1524-1532
220. Ward J.L., Sherali A., Mo Z.P., Tse C.M. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J. Biol. Chem. 275:2000;8375-8381
221. Wardas J. Neuroprotective role of adenosine in the CNS. Pol. J. Pharmacol. 54:2002;313-326
222. Wauquier A., Van Belle H., Van den Broeck W.A., Janssen P.A. Sleep improvement in dogs after oral administration of mioflazine, a nucleoside transport inhibitor. Psychopharmacology. 91:1987;434-439
223. Wilbur S.L., Marchlinski F.E. Adenosine as an antiarrhythmic agent. Am. J. Cardiol. 79:1997;30-37
224. Williams M. Purines: from premise to promise. J. Auton. Nerv. Syst. 81:2000;285-288
225. Williams E.F., Barker P.H., Clanachan A.S. Nucleoside transport in heart: species differences in nitrobenzylthioinosine binding, adenosine accumulation, and drug-induced potentiation of adenosine action. Can. J. Physiol. Pharm. 62:1984;31-37
226. Yamasaki K., Tanaka M., Yokota R., Fujiwara H., Sasayama S. Dilazep dihydrochloride prolongs the infarct size-limiting effect of ischemic preconditioning in rabbits. Heart Vessels. 15:2000;227-232
227. Yang X., Zhu Q., Claydon M.A., Hicks G.L. Jr., Wang T. Enhanced functional preservation of cold-stored rat heart by a nucleoside transport inhibitor. Transplantation. 58:1994;28-34
228. Yao S.Y., Ng A.M., Muzyka W.R., Griffiths M., Cass C.E., Baldwin S.A., Young J.D. Molecular cloning and functional characterization of nitrobenzylthioinosine (NBMPR)-sensitive (es) and NBMPR-insensitive (ei) equilibrative nucleoside transporter proteins (rENT1 and rENT2) from rat tissues. J. Biol. Chem. 272:1997;28423-28430
229. Yeung P.K., Mosher S.J., Macrae D.A., Klassen G.A. Effect of diltiazem and its metabolites on the uptake of adenosine in blood: an in-vitro investigation. J. Pharm. Pharmacol. 43:1991;685-689
230. Zughaib M.E., Abd-Elfattah A.S., Jeroudi M.O., Sun J., Sekili S., Tang X., Bolli R. Augmentation of endogenous adenosine attenuates myocardial 'stunning' independently of coronary flow or hemodynamic effects. Circulation. 88:1993;2359-2369